Thank you very much for the question, Mr. Savard-Tremblay.
Let me first finish my answer to the previous question.
The revision submitted a few days ago by South Africa and India clarifies some points and provides countries with more possibilities. It allows them to decide whether or not they want to grant the waiver.
First, the revised text specifies that the property rights are to be waived on diagnostic instruments, vaccines, medical devices, personal protective equipment, their materials or components, and all means of manufacture for the prevention, treatment or containment of COVID-19. That is the first point that was revised in the latest text.
Second, it specifies the duration for which the waiver is requested. The request is that the waiver be in force for at least 3 years from the date of the current decision. The TRIPS Council will then have the right to review the existence of the exceptional circumstances that do or do not justify the waiver.
Third, it specifies that the General Council shall review the waiver not later than one year after it is granted, and thereafter annually until the waiver terminates, that is to say, up to a maximum of three years.
Fourth, it specifies that WTO members shall not challenge any measures taken in conformity with the provision of the waivers contained in the decision.
As you can see, the current text clarifies some points that were ambiguous or vague in the first submission. The partner countries therefore have a much more concrete and complete text to inform their discussions, as they decide whether or not they will grant the waiver.